Evaluation of alternate-day valganciclovir prophylaxis for cytomegalovirus disease prevention in moderate risk renal transplant patients: A retrospective observational study

Evaluation of alternate-day valganciclovir prophylaxis for cytomegalovirus disease prevention in moderate risk renal transplant patients: A retrospective observational study

Background: Despite valganciclovir (VGCV) being the recommended agent for Cytomegalovirus (CMV) disease prevention, its optimal dose that maintains parity between the efficacies, toxicity profile, and most importantly, the cost has yet to be established. This study is the first to evaluate alternate...

Full description

Bibliographic Details
Main Authors:	Puneet Bhuwania, Ilangovan Veerappan, Ramaswami Sethuraman
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2021-01-01
Series:	Indian Journal of Transplantation
Subjects:	cluster of differentiation 3 count cytomegalovirus mycophenolic acid area-under-curve tac trough vanganciclovir
Online Access:	http://www.ijtonline.in/article.asp?issn=2212-0017;year=2021;volume=15;issue=2;spage=104;epage=110;aulast=Bhuwania

Similar Items

Efficacy of Low Dose Valganciclovir Prophylaxis for Cytomegalovirus Infection in Kidney Transplantation
by: Ümit Özçelik, et al.
Published: (2020-01-01)

Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia
by: Arindam Singha, et al.
Published: (2021-04-01)

Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?: A mini-review
by: Alice Tung Wan Song, et al.

Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation
by: O Manuel, et al.
Published: (2007-12-01)

CMV retinitis in patients on mycophenolate immunosuppression: a report of two cases
by: Prem N. Patel, et al.
Published: (2023-08-01)

Pharmacokinetic study of mycophenolic acid in Iranian kidney transplant patients.
by: Kheirollah Gholami, et al.
Published: (2015-10-01)

Risk factors for cytomegalovirus disease in seropositive renal transplant recipients; a single-center case-controlled study
by: Viviana Navarro-Rodríguez, et al.
Published: (2017-07-01)

Onset of valganciclovir resistance in two infants with congenital cytomegalovirus infection
by: Francesca Garofoli, et al.
Published: (2020-09-01)

Refractory ulcerative colitis complicated by cytomegalovirus infection successfully treated with valganciclovir
by: Tiziana Larussa, et al.
Published: (2012-11-01)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
by: Diana D. Wong, et al.
Published: (2022-06-01)

Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation
by: Hyeyoung Kim, et al.
Published: (2014-09-01)

Role of oral valganciclovir in sick preterm with cytomegalovirus virus infection and ventilation dependence
by: Anumodan Gupta, et al.
Published: (2019-01-01)

Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection
by: Evi B. Struble, et al.
Published: (2021-08-01)

Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial
by: Tomas Reischig, et al.
Published: (2018-11-01)

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
by: Siavash Vaziri, et al.
Published: (2014-01-01)

Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma
by: Giuseppe Stragliotto, et al.
Published: (2020-09-01)

Valganciclovir for cytomegalovirus preemptive therapy in patients following allogeneic hematopoietic stem cell transplantation
by: LU Xuan, et al.
Published: (2020-09-01)

Valganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplantation
by: Erin Wade Ticehurst, et al.
Published: (2010-03-01)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
by: Doesch AO, et al.
Published: (2012-10-01)

Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma
by: Mattia Russel Pantalone, et al.
Published: (2022-04-01)

Adoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection
by: Christopher P. Ouellette
Published: (2022-10-01)

Evaluating the Nephrotoxicity of Area-under-the-Curve-Based Dosing of Vancomycin with Concomitant Antipseudomonal Beta-Lactam Antibiotics: A Systematic Review and Meta-Analysis
by: Chia-Yu Chiu, et al.
Published: (2023-03-01)

The relationship between vancomycin AUC/MIC and trough concentration, age, dose, renal function in Chinese critically ill pediatric patients
by: Jihui Chen, et al.
Published: (2021-12-01)

Prophylaxis of Cytomegalovirus Infection in Solid Organ Transplantation, Retrospective Evaluation
by: Albekairy AM, et al.
Published: (2022-06-01)

Improved results after lung transplantation - analysis of factors
by: MP Zalunardo, et al.
Published: (2001-05-01)

Cytomegalovirus DNAemia in kidney transplant recipients after cessation of standard antiviral prophylaxis; estimated rate on Thai cases and implication on efficacy of prophylaxis
by: Won Sriwijitalai, et al.
Published: (2019-05-01)

Oral Valganciclovir Therapy in Infants Aged ≤2 Months with Congenital Cytomegalovirus Disease: A Multicenter, Single-Arm, Open-Label Clinical Trial in Japan
by: Ichiro Morioka, et al.
Published: (2022-06-01)

Treating HIV-associated cytomegalovirus retinitis with oral valganciclovir and intra-ocular ganciclovir by primary HIV clinicians in southern Myanmar: a retrospective analysis of routinely collected data
by: Jillian Murray, et al.
Published: (2020-11-01)

Cytomegalovirus colitis in a human immunodeficiency virus seropositive individual with moderately severe immunodeficiency
by: M.V.S. Subbalaxmi, et al.
Published: (2014-01-01)

Severe pneumonia in mycophenolate mofetil combined with low-dose corticosteroids-treated patients with immunoglobulin A nephropathy
by: Qi-Jun Wan, et al.
Published: (2015-01-01)

First-Day Direct Hyperbillirubinemia in an Infant with Congenital Cytomegalovirus Infection
by: Ahmad Shah farehat, et al.
Published: (2015-09-01)

Cytomegalovirus infection in solid malignancies
by: Amit Kumar Agrawal, et al.
Published: (2020-01-01)

Foscarnet-Resistant Cytomegalovirus Esophagitis with Stricturing
by: Vinaya Gaduputi, et al.
Published: (2013-01-01)

Atypical cytomegalovirus retinitis in an immunocompetent individual with diffuse large B-cell lymphoma posing a diagnostic enigma
by: Amit Kumar Deb, et al.
Published: (2020-01-01)

Cytomegalovirus infection in gastrointestinal tract: A case series of three patients and review of literature
by: Piyush Ranjan, et al.
Published: (2015-07-01)

Evaluation of risk factors for cytomegalovirus DNAemia after end of regular prophylaxis after heart transplantation
by: Moritz Benjamin Immohr, et al.
Published: (2023-11-01)

Rat cytomegalovirus genome scaffold and A033 gene as infection marker in rats
by: Camalxaman, Siti Nazrina
Published: (2013)

Cytomegalovirus-induced hepatitis in children
by: L.A. Khodak, et al.
Published: (2018-04-01)

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
by: A Jayaprakash Patil, et al.
Published: (2010-03-01)

Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study
by: Dukhee Nho, et al.
Published: (2023-09-01)